Literature DB >> 20007580

Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Sinéad Weldon1, Paul McNally, Noel G McElvaney, J Stuart Elborn, Danny F McAuley, Julien Wartelle, Abderrazzaq Belaaouaj, Rodney L Levine, Clifford C Taggart.   

Abstract

Secretory leucoprotease inhibitor (SLPI) is a neutrophil serine protease inhibitor constitutively expressed at many mucosal surfaces, including that of the lung. Originally identified as a serine protease inhibitor, it is now evident that SLPI also has antimicrobial and anti-inflammatory functions, and therefore plays an important role in host defense. Previous work has shown that some host defense proteins such as SLPI and elafin are susceptible to proteolytic degradation. Consequently, we investigated the status of SLPI in the cystic fibrosis (CF) lung. A major factor that contributes to the high mortality rate among CF patients is Pseudomonas aeruginosa infection. In this study, we report that P. aeruginosa-positive CF bronchoalveolar lavage fluid, which contains lower SLPI levels and higher neutrophil elastase (NE) activity compared with P. aeruginosa-negative samples, was particularly effective at cleaving recombinant human SLPI. Additionally, we found that only NE inhibitors were able to prevent SLPI cleavage, thereby implicating NE in this process. NE in excess was found to cleave recombinant SLPI at two novel sites in the NH(2)-terminal region and abrogate its ability to bind LPS and NF-kappaB consensus binding sites but not its ability to inhibit activity of the serine protease cathepsin G. In conclusion, this study provides evidence that SLPI is cleaved and inactivated by NE present in P. aeruginosa-positive CF lung secretions and that P. aeruginosa infection contributes to inactivation of the host defense screen in the CF lung.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007580      PMCID: PMC3404409          DOI: 10.4049/jimmunol.0901716

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function.

Authors:  Jingxuan Yang; Jing Zhu; Dongxu Sun; Aihao Ding
Journal:  Biochim Biophys Acta       Date:  2005-09-30

Review 2.  Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.

Authors:  Stergios Doumas; Alexandros Kolokotronis; Panagiotis Stefanopoulos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

Review 3.  Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.

Authors:  Thomas S Murray; Marie Egan; Barbara I Kazmierczak
Journal:  Curr Opin Pediatr       Date:  2007-02       Impact factor: 2.856

4.  The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses.

Authors:  Jonathan W McMichael; Ali Roghanian; Lu Jiang; Robert Ramage; Jean-Michel Sallenave
Journal:  Am J Respir Cell Mol Biol       Date:  2005-01-24       Impact factor: 6.914

Review 5.  SLPI and elafin: one glove, many fingers.

Authors:  Steven E Williams; Thomas I Brown; Ali Roghanian; Jean-Michel Sallenave
Journal:  Clin Sci (Lond)       Date:  2006-01       Impact factor: 6.124

6.  Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense.

Authors:  Joost B Vos; Marianne A van Sterkenburg; Klaus F Rabe; Joost Schalkwijk; Pieter S Hiemstra; Nicole A Datson
Journal:  Physiol Genomics       Date:  2005-02-08       Impact factor: 3.107

7.  Predictors of mortality in adults with cystic fibrosis.

Authors:  J M Courtney; J Bradley; J Mccaughan; T M O'Connor; C Shortt; C P Bredin; I Bradbury; J S Elborn
Journal:  Pediatr Pulmonol       Date:  2007-06

8.  Cleaved SLPI, a novel biomarker of chymase activity.

Authors:  Stanley M Belkowski; John Masucci; Andrew Mahan; Jukka Kervinen; Matthew Olson; Lawrence de Garavilla; Michael R D'Andrea
Journal:  Biol Chem       Date:  2008-09       Impact factor: 3.915

Review 9.  Proteases and cystic fibrosis.

Authors:  Judith A Voynow; Bernard M Fischer; Shuo Zheng
Journal:  Int J Biochem Cell Biol       Date:  2008-03-14       Impact factor: 5.085

10.  Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding.

Authors:  Clifford C Taggart; Sally-Ann Cryan; Sinead Weldon; Aileen Gibbons; Catherine M Greene; Emer Kelly; Teck Boon Low; Shane J O'neill; Noel G McElvaney
Journal:  J Exp Med       Date:  2005-12-13       Impact factor: 14.307

View more
  39 in total

1.  A model to explain specific cellular communications and cellular harmony:- a hypothesis of coupled cells and interactive coupling molecules.

Authors:  Cyril J Craven
Journal:  Theor Biol Med Model       Date:  2014-09-14       Impact factor: 2.432

2.  A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.

Authors:  Donna M Small; Marie-Louise Zani; Derek J Quinn; Sandrine Dallet-Choisy; Arlene M A Glasgow; Cecilia O'Kane; Danny F McAuley; Paul McNally; Sinéad Weldon; Thierry Moreau; Clifford C Taggart
Journal:  Mol Ther       Date:  2014-09-05       Impact factor: 11.454

3.  A secretory leukocyte protease inhibitor variant with improved activity against lung infection.

Authors:  N Camper; A M A Glasgow; M Osbourn; D J Quinn; D M Small; D T McLean; F T Lundy; J S Elborn; P McNally; R J Ingram; S Weldon; C C Taggart
Journal:  Mucosal Immunol       Date:  2015-09-16       Impact factor: 7.313

Review 4.  Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections.

Authors:  Charles R Wira; Mickey V Patel; Mimi Ghosh; Lucy Mukura; John V Fahey
Journal:  Am J Reprod Immunol       Date:  2011-03       Impact factor: 3.886

5.  Regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in smokers.

Authors:  Megan Meyer; Rebecca N Bauer; Blanche D Letang; Luisa Brighton; Elizabeth Thompson; Rosalia C M Simmen; James Bonner; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-27       Impact factor: 5.464

6.  Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis.

Authors:  Apparao B Kummarapurugu; Daniel K Afosah; Nehru Viji Sankaranarayanan; Rahaman Navaz Gangji; Shuo Zheng; Thomas Kennedy; Bruce K Rubin; Judith A Voynow; Umesh R Desai
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

Review 7.  Cystic Fibrosis: Microbiology and Host Response.

Authors:  Edith T Zemanick; Lucas R Hoffman
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

8.  Neutrophil elastase modulates cytokine expression: contribution to host defense against Pseudomonas aeruginosa-induced pneumonia.

Authors:  Rym Benabid; Julien Wartelle; Laurette Malleret; Nicolas Guyot; Sophie Gangloff; François Lebargy; Azzaq Belaaouaj
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

9.  miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production.

Authors:  Sinéad Weldon; Paul McNally; Danny F McAuley; Irene K Oglesby; Christine L Wohlford-Lenane; Jennifer A Bartlett; Christopher J Scott; Noel G McElvaney; Catherine M Greene; Paul B McCray; Clifford C Taggart
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

10.  Colonization of CF patients' upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa.

Authors:  Wibke Katharina Janhsen; Christin Arnold; Julia Hentschel; Thomas Lehmann; Wolfgang Pfister; Michael Baier; Klas Böer; Kerstin Hünniger; Oliver Kurzai; Uta-Christina Hipler; Jochen Georg Mainz
Journal:  Med Microbiol Immunol       Date:  2016-07-04       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.